Regulation - GlaxoSmithKline, Mergers & Acquisitions

Filter

Popular Filters

India's Elder Pharma to enter EU markets; comment on GSK Indian OTC moves

26-11-2012

Indian drugmaker Elder Pharmaceuticals says it is ready to enter the European Union market following…

Asia-PacificdiosminElder PharmaceuticalsEuropeGenericsGlaxoSmithKlineMarkets & MarketingMergers & AcquisitionsPharmaceuticalRegulation

US FDA clears Amarin's Vascepa, a competitor for Lovaza

30-07-2012

The US Food and Drug Administration has approved biotech firm Amarin's (Nasdaq: AMRN) Vascepa (icosapent…

AmarinBiotechnologyCardio-vascularGlaxoSmithKlineLovazaMergers & AcquisitionsNorth AmericaRegulationVascepa

GSK and Theravance file for FF/VI approval in the USA and Europe; Talks with Human Genome?

16-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) announced on Friday…

BiotechnologyBreoEuropeGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsNorth AmericaPharmaceuticalRegulationRelovairRelvarRespiratory and PulmonaryTheravance

GlaxoSmithKline pulls sNDA for Tykerb plus Herceptin; Watson/Actavis update

13-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) revealed yesterday that it has withdrawn a supplemental New…

ActavisGenericsGlaxoSmithKlineHerceptinMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalRegulationRocheTykerbWatson Pharmaceuticals

News briefs: GlaxoSmithKline and Bayer

24-05-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) has said it would not proceed with its $2.59 billion hostile…

Antibiotics and Infectious diseasesBayerGlaxoSmithKlineMergers & AcquisitionsOncologyPharmaceuticalregorafenibRegulationResearch

Parexel

Parexel

Back to top